Cybis™ 10:25 THC:CBD oil

Small molecule

CCymra Life Sciences

Cybis™ 10:25 THC:CBD oil is one of 15 small molecule programs targeting Neck pain. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neck PainActive, not recruiting

Neck PainPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

19 competitors in Neck Pain

#DrugCompanyPhaseTrials

Epidiolex

Advil

3 3

Marcaine

IInnocoll

Approved

1 4

Oxycontin

PProtega

Approved

—5

Versed

CConrado Roberto Hoffmann Filho

Approved

—6

Vivarin

HHikma Pharmaceuticals LLC

Phase 3

1 7

Tylenol

KKenvue Brands

Phase 2

1 8

Aspercreme Warming

AAveritas Pharma, Inc.

Phase 2

1 9

Non-Steroidal Anti-Inflammatory Drugs (NSAID)

Roche

Phase 2

1 10

Xylocaine

MMEDRx USA, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Neck pain1 trial

A Study of Cybis™ 10:25 THC:CBD Oil in Adults With Chronic Back/Neck Pain

Completed·CCymra Life Sciences·Phase 1/2·NCT04976738·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cybis™ 10:25 THC:CBD oil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cybis™ 10:25 THC:CBD oil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cybis™ 10:25 THC:CBD oil. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cymra Life Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: CCymra Life Sciences

Cybis™ 10:25 THC:CBD oil

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Neck pain1 trial

References

Drug Info

Quick Facts

Related News